{"id":"continuation-of-insulin-glargine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine is a recombinant human insulin analog modified to have an extended duration of action (approximately 24 hours). It binds to the insulin receptor on target tissues, facilitating glucose transport into muscle and adipose tissue while suppressing gluconeogenesis and glycogenolysis in the liver. This provides steady basal insulin coverage for glycemic control in diabetes.","oneSentence":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake into cells and inhibiting hepatic glucose production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:57.678Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01854723","phase":"PHASE4","title":"Comparison Study of Insulin Glargine and NPH Insulin","status":"WITHDRAWN","sponsor":"Providence Health & Services","startDate":"2013-04","conditions":"Diabetes","enrollment":""},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT02694289","phase":"NA","title":"Effects of Metformin in Heart Failure Patients","status":"WITHDRAWN","sponsor":"Maya Guglin","startDate":"2016-11","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00437112","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-02","conditions":"Diabetes Mellitus, Type 2","enrollment":142},{"nctId":"NCT00971659","phase":"PHASE1","title":"Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lantus"],"phase":"marketed","status":"active","brandName":"Continuation of insulin glargine","genericName":"Continuation of insulin glargine","companyName":"Providence Health & Services","companyId":"providence-health-services","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake into cells and inhibiting hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}